N-acetylcysteine enhances the antipsychotic effect of aripiprazole in the neurodevelopmental rat model of schizophrenia
Pharmacology Biochemistry and Behavior · 2025
DOI: 10.1016/j.pbb.2025.174028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Biochemistry and Behavior, 2025. Verfasst von Zofia Rogóż und 2 weiteren Autor:innen. Beteiligte Einrichtung: Maj Institute of Pharmacology Polish Academy of Sciences, Department of Pharmacology and Brain Biostructure, Kraków, Poland; University of Applied Sc…. Hauptthemen laut MEDLINE: Acetylcysteine, Aripiprazole, Schizophrenia, Antipsychotic Agents. Die Arbeit nennt 62 Literaturangaben. Gefördert von: Polska Akademia Nauk, Maj Institute of Pharmacology Polish Academy of Sciences.
Abstract (Originalsprache)
Symptoms of schizophrenia are well characterized, but the mechanism underlying the pathogenesis of the disease still remains unknown. In addition, therapy of negative symptoms and cognitive deficits in schizophrenic patients is a serious clinical problem. Some clinical studies have shown that the atypical antipsychotic drug aripiprazole (ARI), and the antioxidant N-acetylcysteine (NAC) are effective in reducing positive and negative symptoms of schizophrenia in patients. The aim of the present study was to evaluate the influence of repeated co-treatment with low doses of ARI and NAC on the schizophrenia-like behavior in adult rats. The schizophrenia-like behavior was induced in Sprague-Dawley male pups in the neonatal days p5-p16 by repeated administration of the glutathione synthesis inhibitor L-butionine-(S,R)-sulfoximine (BSO) given together with the dopamine reuptake inhibitor 1-[2-[Bis-4(fluorophenyl)methoxy]ethyl]-4-3-(3-phenylpropyl) (GBR 12909). Adult rats received repeated co-treatment with ARI (0.1 mg/kg) and NAC (10 mg/kg) for 21 days, and their effects on schizophrenia-like behavior were assessed (on p90-91) using the social interaction test and novel object recognition test. The present data indicated that the studied drugs at higher doses: ARI (0.3 mg/kg but not 0.1 mg/kg) and NAC (30 mg/kg but not 10 mg/kg) reversed schizophrenia-like symptoms in the tested model. Moreover, repeated co-treatment with low doses of ARI with NAC also reversed schizophrenia-like behavior in the neurodevelopmental rat model of schizophrenia. The above results indicated that NAC enhanced the action of ARI in the used neurodevelopmental rat model of schizophrenia, and the mechanism of action of the used drugs in this model is discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Maj Institute of Pharmacology Polish Academy of Sciences, Department of Pharmacology and Brain Biostructure, Kraków, Poland; University of Applied Sciences, Institute of Health, Faculty of Cosmetology, Nowy Targ, Poland.
- Maj Institute of Pharmacology Polish Academy of Sciences, Department of Pharmacology and Brain Biostructure, Kraków, Poland.
- Maj Institute of Pharmacology Polish Academy of Sciences, Department of Neurochemistry, Kraków, Poland. Electronic address: wasik@if-pan.krakow.pl.
Förderung
- Polska Akademia Nauk
- Maj Institute of Pharmacology Polish Academy of Sciences
Zitieren
APA
Rogóż, Z., Kamińska, K., & Wąsik, A. (2025). N-acetylcysteine enhances the antipsychotic effect of aripiprazole in the neurodevelopmental rat model of schizophrenia. Pharmacology Biochemistry and Behavior. https://doi.org/10.1016/j.pbb.2025.174028
Vancouver
Rogóż Z, Kamińska K, Wąsik A. N-acetylcysteine enhances the antipsychotic effect of aripiprazole in the neurodevelopmental rat model of schizophrenia. Pharmacology Biochemistry and Behavior. 2025. doi:10.1016/j.pbb.2025.174028
BibTeX
@article{Rog2025,
author = {Rogóż, Zofia and Kamińska, Kinga and Wąsik, Agnieszka},
title = {N-acetylcysteine enhances the antipsychotic effect of aripiprazole in the neurodevelopmental rat model of schizophrenia},
journal = {Pharmacology Biochemistry and Behavior},
year = {2025},
doi = {10.1016/j.pbb.2025.174028}
}
EUVIMED